ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,587.00
0.23%
S&P ASX All Technology
2,972.40
0.12%
Brent Oil
83.985
0.53%
US Dollar vs AUD
1.52926
-0.11%
Bitcoin
57,879.36
-0.62%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Genuit Group Plc (GEN)

  7. Genuit Group Plc (GEN) News

GEN

Genuit (GEN)

Genuit Group Plc
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:GEN
DateTimeSourceHeadlineSymbolCompany
24/04/202419:39RNS Regulatory NewsGenuit Group PLC Notice of AGMLSE:GENGenuit Group Plc
11/04/202401:24RNS Regulatory NewsGenuit Group PLC Director/PDMR ShareholdingLSE:GENGenuit Group Plc
11/04/202401:17RNS Regulatory NewsGenuit Group PLC Director/PDMR ShareholdingLSE:GENGenuit Group Plc
10/04/202401:28RNS Regulatory NewsGenuit Group PLC Director DeclarationLSE:GENGenuit Group Plc
03/04/202401:56RNS Regulatory NewsGenuit Group PLC Director/PDMR ShareholdingLSE:GENGenuit Group Plc
21/03/202402:27RNS Regulatory NewsGenuit Group PLC Director/PDMR ShareholdingLSE:GENGenuit Group Plc
12/03/202421:40Alliance NewsAlliance NewsGenuit revenue drops on lower divisional sales but profit surgesLSE:GENGenuit Group Plc
12/03/202418:09Alliance NewsAlliance News*Genuit says 2024 trading has started in line w/ expectations, despite market uncertaintyLSE:GENGenuit Group Plc
12/03/202418:09Alliance NewsAlliance News*Genuit declares total dividend per share of 12.4p vs 12.3p YoYLSE:GENGenuit Group Plc
12/03/202418:07Alliance NewsAlliance News*Genuit 2023 pretax profit GBP48.4m vs GBP45.4m YoYLSE:GENGenuit Group Plc
12/03/202418:00RNS Regulatory NewsGenuit Group PLC Final ResultsLSE:GENGenuit Group Plc
01/03/202419:30RNS Regulatory NewsGenuit Group PLC Director DeclarationLSE:GENGenuit Group Plc
19/02/202420:00RNS Regulatory NewsGenuit Group PLC Notice of Results and Investor PresentationLSE:GENGenuit Group Plc
24/01/202402:49UK RegulatoryGenuit Group PLC Holding(s) in CompanyLSE:GENGenuit Group Plc
23/01/202422:24UK RegulatoryGenmab A/S Genmab Announces Net Sales Of Darzalex(R) (daratumumab) For 2023LSE:GENGenuit Group Plc
23/01/202410:40UK RegulatoryGenmab A/S Genmab Announces Decision In Arbitration Appeal Under License Agreement With JanssenLSE:GENGenuit Group Plc
09/01/202422:45UK RegulatoryGenmab A/S Tivdak(R) (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted For Priority Review By U.S. Food And Drug Administration For Patients With Recurrent Or Metastatic Cervical CancerLSE:GENGenuit Group Plc
03/01/202416:55UK RegulatoryGenmab A/S Transactions With Shares And Linked Securities In Genmab A/S Made By Managerial Employees And Their Closely Associated PersonsLSE:GENGenuit Group Plc
03/01/202401:52UK RegulatoryGenmab A/S Genmab To Present At The 42nd Annual J.P. Morgan Healthcare ConferenceLSE:GENGenuit Group Plc
12/12/202323:00UK RegulatoryGenmab A/S Genmab To Hold 2023 R&D Update And Ash Data Review MeetingLSE:GENGenuit Group Plc
10/12/202304:00UK RegulatoryGenmab A/S New Pivotal Data For Bispecific Antibody Epcoritamab (DuoBody(R) Cd3xcd20) Demonstrates High Overall And Complete Responses In Patients With Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)LSE:GENGenuit Group Plc
06/12/202309:26UK RegulatoryGenmab A/S Capital Increase In Genmab As A Result Of Employee Warrant ExerciseLSE:GENGenuit Group Plc
27/11/202323:00UK RegulatoryGenmab A/S Genmab Announces Positive Regulatory Updates For Epcoritamab (EPKINLY(R)/Tepkinly(R)) For The Treatment Of Relapsed/Refractory Follicular LymphomaLSE:GENGenuit Group Plc
22/11/202318:00UK RegulatoryGenuit Group PLC Strategy Progress Update NotificationLSE:GENGenuit Group Plc
22/11/202308:45UK RegulatoryGenmab A/S Transactions With Shares And Linked Securities In Genmab A/S Made By Managerial Employees And Their Closely Associated PersonsLSE:GENGenuit Group Plc
22/11/202308:42UK RegulatoryGenmab A/S Grant Of Restricted Stock Units To Board Members And Employees And Grant Of Warrants To Employees In GenmabLSE:GENGenuit Group Plc
15/11/202320:03Alliance NewsAlliance NewsGenuit shares rise as annual profit predicted to exceed expectationsLSE:GENGenuit Group Plc
15/11/202318:00UK RegulatoryGenuit Group PLC Trading UpdateLSE:GENGenuit Group Plc
10/11/202301:14UK RegulatoryGenmab A/S Major Shareholder AnnouncementLSE:GENGenuit Group Plc
09/11/202321:08UK RegulatoryGenuit Group PLC Director DeclarationLSE:GENGenuit Group Plc
 Showing the most relevant articles for your search:LSE:GEN

Your Recent History

NYSE
KO
Coca Cola
ASX
WDC
Westfield
ASX
WBC
Westpac Banking
ASX
CBA
Commonwealth Bank Of Aus...
NASDAQ
TSLA
Tesla
ASX
XAO
Australian SE All Ordina...
NASDAQ
AAPL
Apple
COIN
ETHUSD
Ethereum
PM
XAUUSD
Gold vs US Dollar
ASX
ORG
Origin Energy
ASX
MQG
Macquarie
ASX
XTO
S&P ASX 100
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NASDAQ
AMZN
Amazon.com
ASX
XFL
S&P ASX 50
NYSE
MRK
Merck
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved